Intercure (INCR) vs SCYNEXIS (SCYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SCYNEXIS (SCYX) has outperformed Intercure (INCR) over the past year, losing 32.1% versus a loss of 37.5%. Over five years, INCR leads with a -85.8% price change compared with -90.5% for SCYX. Intercure is the larger company by market cap ($75.5 million vs $42.0 million), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INCR | SCYX |
|---|---|---|
| Share price | $5.03 | $4.22 |
| Market cap | $75.47M | $41.99M |
| 1-day change | -1.95% | -11.72% |
| YTD return | +10.55% | -16.53% |
| 1-year return | -37.52% | -32.11% |
| 5-year return | -85.81% | -90.53% |
| EPS (TTM) | $-0.95 | $-0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $9.12 |
| 52-week low | $3.40 | $3.53 |
| Distance from 52-week high | -40.12% | -53.73% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +760.90% |
| Average volume | 21.73K | 279.10K |
| Shares outstanding | 15.00M | 9.95M |
| Employees | 285 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
INCR vs SCYX FAQ
Which is bigger, Intercure or SCYNEXIS?
Intercure (INCR) is larger, with a market capitalization of $75.47M compared with $41.99M for SCYNEXIS (SCYX).
Which stock has performed better over the past year, INCR or SCYX?
SCYX returned -32.11% over the past 12 months, compared with -37.52% for INCR (price return, excluding dividends). Past performance does not predict future results.
Are Intercure and SCYNEXIS in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.